LYB005FA2 60µg group:Vaccination with 60 µg of recombinant respiratory syncytial virus vaccine (CHO cells) (A01B adjuvant), 0.5ml, 0 days of immunization procedure

2 trials

Sponsors

Hubei Provincial Center for Disease Control and Prevention, Hubei Provincial Center for Disease Prevention and Control

Conditions

Acute respiratory infection.

Phase 1

Phase ? Randomized, Blinded, Placebo-controlled Clinical Trial on the Safety and Immunogenicity of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells) in Healthy People Aged 18 Years and Older

Active, not recruitingChiCTR2500108280

Hubei Provincial Center for Disease Control and PreventionAcute respiratory infection.

Start: 2025-04-15Updated: 2025-09-01

Phase 2

A Phase II Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Adults Aged 60 Years and Above

Active, not recruitingChiCTR2500113441

Hubei Provincial Center for Disease Prevention and ControlAcute respiratory infection.

Start: 2025-10-27Updated: 2025-12-01